The price of Royalty Pharma plc (NASDAQ: RPRX) closed at $32.24 in the last session, up 0.06% from day before closing price of $32.22. On the day, 2273916 shares were traded. RPRX stock price reached its highest trading level at $32.39 during the session, while it also had its lowest trading level at $32.02.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
We take a closer look at RPRX’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.54 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 566.02. For the most recent quarter (mrq), Quick Ratio is recorded 2.40 and its Current Ratio is at 2.40. In the meantime, Its Debt-to-Equity ratio is 1.20 whereas as Long-Term Debt/Eq ratio is at 1.03.
Upgrades & Downgrades
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on May 24 when Legorreta Pablo G. bought 150,000 shares for $32.25 per share. The transaction valued at 4,837,440 led to the insider holds 380,000 shares of the business.
RIGGS RORY B sold 1,750,000 shares of RPRX for $57,435,000 on May 22. The Director now owns 6,762 shares after completing the transaction at $32.82 per share. On May 17, another insider, Legorreta Pablo G., who serves as the CEO, Chairman of the Board of the company, bought 69,612 shares for $32.94 each. As a result, the insider paid 2,293,096 and bolstered with 230,000 shares of the company.
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RPRX now has a Market Capitalization of 15.54B and an Enterprise Value of 20.07B. As of this moment, Royalty’s Price-to-Earnings (P/E) ratio for their current fiscal year is 42.70, and their Forward P/E ratio for the next fiscal year is 8.20. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 6.78. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.28 while its Price-to-Book (P/B) ratio in mrq is 2.41. Its current Enterprise Value per Revenue stands at 8.51 whereas that against EBITDA is 25.13.
Stock Price History:
Over the past 52 weeks, RPRX has reached a high of $44.66, while it has fallen to a 52-week low of $32.02. The 50-Day Moving Average of the stock is 35.18, while the 200-Day Moving Average is calculated to be 39.15.
According to the various share statistics, RPRX traded on average about 1.92M shares per day over the past 3-months and 2.18M shares per day over the past 10 days. A total of 445.61M shares are outstanding, with a floating share count of 172.08M. Insiders hold about 0.10% of the company’s shares, while institutions hold 68.40% stake in the company. Shares short for RPRX as of Apr 27, 2023 were 7.75M with a Short Ratio of 7.18M, compared to 7.55M on Mar 30, 2023. Therefore, it implies a Short% of Shares Outstanding of 1.73% and a Short% of Float of 1.80%.
Dividends & Splits
The forward annual dividend rate for RPRX is 0.80, which was 0.77 in the trailing 12 months. Against a Trailing Annual Dividend Yield of 2.39%, it implies a Forward Annual Dividend Yield of 2.42%.
The company has 5 analysts who recommend its stock at the moment. On average, analysts expect EPS of $0.83 for the current quarter, with a high estimate of $0.89 and a low estimate of $0.78, while EPS last year was $0.79. The consensus estimate for the next quarter is $0.78, with high estimates of $0.89 and low estimates of $0.7.
Analysts are recommending an EPS of between $4.35 and $4 for the fiscal current year, implying an average EPS of $4.12. EPS for the following year is $3.93, with 7 analysts recommending between $4.37 and $3.62.
According to 3 analysts, the current quarter’s revenue is expected to be $550.29M. It ranges from a high estimate of $565.65M to a low estimate of $539M. As of the current estimate, Royalty Pharma plc’s year-ago sales were $536M, an estimated increase of 2.70% from the year-ago figure. For the next quarter, 3 analysts are estimating revenue of $605.2M, an increase of 3.10% over than the figure of $2.70% in the same quarter last year. There is a high estimate of $628M for the next quarter, whereas the lowest estimate is $588.31M.
A total of 6 analysts have provided revenue estimates for RPRX’s current fiscal year. The highest revenue estimate was $2.97B, while the lowest revenue estimate was $2.51B, resulting in an average revenue estimate of $2.86B. In the same quarter a year ago, actual revenue was $2.24B, up 27.70% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $2.74B in the next fiscal year. The high estimate is $3.03B and the low estimate is $2.51B. The average revenue growth estimate for next year is down -4.20% from the average revenue estimate for this year.